Wall Street Zen Upgrades Aclarion (NASDAQ:ACON) to “Hold”

Aclarion (NASDAQ:ACON) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Aclarion Stock Performance

Shares of Aclarion stock opened at $2.54 on Friday. The stock has a market cap of $2.16 million, a price-to-earnings ratio of -0.17 and a beta of 1.44. The stock has a 50 day moving average price of $4.20 and a 200-day moving average price of $6.23. Aclarion has a one year low of $2.34 and a one year high of $229.50.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.